Children’s Hospital of Philadelphia activated as new center for ZEVASKYN gene therapy for rare skin disease.

Abeona Therapeutics has activated the Children’s Hospital of Philadelphia (CHOP) as the sixth Qualified Treatment Center for ZEVASKYN, a gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), a rare and severe skin disorder. This expansion improves access to the treatment on the U.S. East Coast, allowing more patients to benefit from this innovative therapy that promotes wound healing and pain reduction. CHOP’s involvement highlights its leadership in pediatric care and gene therapy. Patients can contact CHOP or Abeona Assist for treatment and support services.